Cargando…
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
BACKGROUND: Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (...
Autores principales: | Ono, Taihei, Igawa, Satoshi, Ozawa, Takahiro, Kasajima, Masashi, Ishihara, Mikiko, Hiyoshi, Yasuhiro, Kusuhara, Seiichiro, Nishinarita, Noriko, Fukui, Tomoya, Kubota, Masaru, Sasaki, Jiichiro, Hisashi, Mitsufuji, Katagiri, Masato, Naoki, Katsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590234/ https://www.ncbi.nlm.nih.gov/pubmed/30821083 http://dx.doi.org/10.1111/1759-7714.13018 |
Ejemplares similares
-
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019) -
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019) -
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021) -
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018) -
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)